Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Polymyositis

In brief

This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).

Key facts

Study ID
NCT01801917
Run by
Novartis Pharmaceuticals
People needed
14
Starts
2013-04-24
Expected to finish
2016-08-05
Last updated by the study team
2021-01-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.